Powered by CardioMender, MD  |  📍 17009 Pines Blvd, Pembroke Pines, FL  |  Serving Florida Residents Exclusively (954) 799-6439
Home › Blog › Zepbound vs. Wegovy: Which GLP-1 Actually Gets You Better Results?
Weight Loss Articles October 24, 2026 12 min read

Zepbound vs. Wegovy: Which GLP-1 Actually Gets You Better Results?

Reviewed by the CardioMender, MD Medical Team In the only head-to-head randomized trial so far, Zepbound® (tirzepatide) produced more average weight loss than Wegovy® (semaglutide): about 20.2% of body weight versus 13.7% after 72 weeks. That is an average across a study group, though, not a promise for any one person, and results may vary.…

AA
Aaron Welch
CardioMender, MD Medical Team
Zepbound vs. Wegovy: Which GLP-1 Actually Gets You Better Results?
Ready to take control of your health? Speak with our physician team to find the right program for you.
Book Free Consult

Reviewed by the CardioMender, MD Medical Team

In the only head-to-head randomized trial so far, Zepbound® (tirzepatide) produced more average weight loss than Wegovy® (semaglutide): about 20.2% of body weight versus 13.7% after 72 weeks. That is an average across a study group, though, not a promise for any one person, and results may vary. At Cardiomender Weight Loss & Aesthetics in Pembroke Pines, we see the “better” medication depend on your health history, your tolerance and what your plan covers, not on one number alone.

Key Takeaways

  • In the SURMOUNT-5 trial, average weight change was −20.2% with tirzepatide versus −13.7% with semaglutide at 72 weeks (22.8 kg vs. 15.0 kg).
  • Waist circumference fell 18.4 cm with tirzepatide versus 13.0 cm with semaglutide.
  • Stopping treatment because of stomach-related side effects was less common with tirzepatide (2.7%) than with semaglutide (5.6%) in that trial.
  • The two drugs carry different additional FDA-approved indications: moderate-to-severe obstructive sleep apnea with Zepbound, and cardiovascular risk reduction in adults with known heart disease with Wegovy.
  • Both carry a boxed warning for thyroid C-cell tumors and both require medical evaluation and ongoing supervision.

Quick answer: Zepbound vs. Wegovy at a glance

Feature Zepbound (tirzepatide) Wegovy (semaglutide)
How it works Activates GIP and GLP-1 receptors Activates GLP-1 receptors
Form Once-weekly injection Once-weekly injection
Weight management indication Adults with obesity, or overweight plus at least one weight-related condition, alongside diet and activity Adults (and patients 12+) with obesity, or adults with overweight plus a weight-related condition, alongside diet and activity
Additional FDA indication Moderate-to-severe obstructive sleep apnea in adults with obesity Reducing risk of major cardiovascular events in adults with known heart disease and obesity or overweight
72-week head-to-head result −20.2% body weight −13.7% body weight
Boxed warning Thyroid C-cell tumors Thyroid C-cell tumors

We have left dollar figures out on purpose. Cost and coverage vary by insurance plan and change over time, so the zepbound vs wegovy cost question is best answered against your own plan (see the cost section below).

What is the difference between Wegovy and Zepbound?

Both medications mimic gut hormones that help regulate appetite and blood sugar. Wegovy contains semaglutide, which activates the GLP-1 (glucagon-like peptide-1) receptor. Zepbound contains tirzepatide, which activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. That dual action is the main pharmacological difference between tirzepatide vs semaglutide.

Zepbound and Mounjaro® contain the same molecule, sold under different brand names and indications; our page on tirzepatide, Mounjaro and Zepbound explains the split. For a generic-name overview, see our semaglutide vs. tirzepatide guide.

Zepbound vs. Wegovy weight loss: what the head-to-head trial found

Most comparisons you read online stack one drug’s trial next to another’s. SURMOUNT-5, published in the New England Journal of Medicine, compared the two directly. According to a summary by the American College of Cardiology, the phase 3b trial enrolled 751 adults with obesity (or overweight with complications) but without diabetes, at 32 sites in the U.S. and Puerto Rico, and lasted 72 weeks.

  • Weight: −20.2% (22.8 kg) with tirzepatide vs. −13.7% (15.0 kg) with semaglutide, p<0.001.
  • Waist circumference: −18.4 cm vs. −13.0 cm, p<0.001.
  • Weight-loss thresholds: more people on tirzepatide reached 10% to 25% reductions in body weight.
  • Sex differences: men lost roughly 6% less than women in both groups.

So for the question of zepbound vs wegovy weight loss, tirzepatide came out ahead on average in this trial. Two honest caveats: the trial was open-label (participants and clinicians knew which drug was used), and an average is not your individual outcome. Some people do very well on semaglutide; others lose less than the average on either drug. Our pages on tirzepatide weight loss results and how much weight you can lose on semaglutide go deeper on each drug.

Which is better, Wegovy or Zepbound?

Patients often ask which is better, Wegovy or Zepbound, and the honest answer has layers. On average weight loss, the Wegovy vs Zepbound comparison favors Zepbound in the only direct trial. On approved uses, they differ: one has a sleep apnea indication and the other a cardiovascular one. On tolerability, both cause stomach-related effects, with fewer discontinuations for that reason on tirzepatide in SURMOUNT-5. And on practical matters such as insurance, availability and your own history, the answer can flip. This is why the decision belongs in a medical visit rather than a comparison chart.

The same logic applies when the question is tirzepatide vs semaglutide for weight loss at the generic-name level: the molecules behind the brand names are what the trial actually tested, and the same average-versus-individual caveat applies.

What we look at before recommending either drug

During an evaluation, we review your medical and family history, current medications, prior attempts at weight loss, any weight-related conditions such as high blood pressure, and how you have handled stomach-related side effects in the past. Baseline lab work helps us understand your overall health, and we discuss realistic expectations, including that some people lose less than trial averages. Our aim is a plan you can follow safely, not the largest possible number on the scale.

Why a head-to-head trial matters

Different trials enroll different people, use different follow-up lengths and run under different conditions. Comparing the earlier separate trials of each drug can mislead. A randomized head-to-head design removes much of that noise, which is why we anchor this article on it.

Is Zepbound better than Wegovy for everyone?

On average weight loss, the trial favored tirzepatide. But “is Zepbound better than Wegovy” is a different question from “which is better for you.” Approved uses differ:

  • Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, in addition to weight management. If sleep apnea is part of your picture, see our page on tirzepatide and sleep apnea.
  • Wegovy is FDA-approved to reduce the risk of major cardiovascular events (such as heart attack or stroke) in adults with known heart disease and obesity or overweight. This is based on the SELECT trial of 17,604 adults, in which 6.5% of Wegovy-treated patients had a major cardiovascular event vs. 8.0% on placebo. If you have established heart disease, this indication matters.

Neither drug is approved for anything outside those indications, and we do not suggest using either one that way. Blood pressure is a common question; see semaglutide and blood pressure and tirzepatide and blood pressure. Tolerability and access also count: the best drug is one you can take consistently, safely and afford.

Side effects: Zepbound vs. Wegovy

The tirzepatide vs semaglutide side effects picture is similar, because both drugs slow digestion and act on appetite pathways. According to the prescribing information, common effects include nausea, diarrhea, vomiting, constipation, abdominal pain and indigestion. In SURMOUNT-5, most adverse events were mild to moderate and occurred during dose escalation, and stopping due to stomach-related events was 2.7% with tirzepatide vs. 5.6% with semaglutide. In the SELECT trial, 16% of Wegovy patients stopped for adverse events versus 8% on placebo, mostly stomach-related.

Boxed warning: both drugs carry a boxed warning about thyroid C-cell tumors, seen in rodents; the human risk is not well understood. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Your clinician will also review other conditions and medications before prescribing.

Practical guides: semaglutide side effects, how to ease nausea, hair shedding on tirzepatide and semaglutide, and muscle loss on tirzepatide. Call your clinician about severe or persistent symptoms.

How fast does each work?

Both are started at a low dose and increased gradually, which is why early weeks focus on tolerability rather than peak effect. Timing varies from person to person, and results may vary. Our guides cover how long tirzepatide takes to work and how long semaglutide takes to work.

A checklist for your clinician conversation

This is not a way to choose a medication yourself; it is a list of topics to bring to a medical evaluation.

  1. Do you have known heart disease, or moderate-to-severe sleep apnea?
  2. Any personal or family history of medullary thyroid carcinoma or MEN 2?
  3. How have you tolerated stomach-related side effects on past medications?
  4. Are you pregnant, planning pregnancy or breastfeeding?
  5. Which other medications and supplements do you take?
  6. What does your insurance cover, and what is your realistic budget?
  7. What nutrition and activity support will you have?

Diet and lifestyle on either medication

Both drugs are approved alongside a reduced-calorie diet and increased physical activity, and trial participants received lifestyle support, so the published numbers assume it. Start with what to eat on tirzepatide, what to eat on semaglutide, our nutrition guidance and exercise for weight loss.

Cost and coverage

Coverage differs by plan, employer and diagnosis, and it changes. Ask your insurer whether each medication is covered for your indication, and whether prior authorization applies. You may see compounded versions advertised; our page on compounded semaglutide and tirzepatide explains what to know first.

Choosing between Zepbound and Wegovy with a South Florida care team

CardioMender has helped patients with weight loss since 2009, well before GLP-1 drugs became common. Care is in person at our Pembroke Pines clinic, not just a prescription by video. Our approach pairs medical evaluation with nutrition guidance, lab work, B-vitamin injections and monitoring, and aims at lifestyle change and maintenance rather than indefinite dependence on medication.

Explore tirzepatide treatment in Pembroke Pines, semaglutide treatment in Pembroke Pines, Zepbound weight loss, our weight loss program and medical weight loss. You can meet our team online.

Frequently Asked Question

Is Zepbound stronger than Wegovy?

In SURMOUNT-5, average weight loss was greater with tirzepatide (−20.2% vs. −13.7%). “Stronger” is not the same as “right for you,” and individual results vary.

Which is better, Wegovy or Zepbound, for sleep apnea?

Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity; Wegovy is not approved for that indication. A clinician should confirm the diagnosis and plan.

Can you switch from Wegovy to Zepbound, or the reverse?

Switching can be appropriate, but only under a prescriber’s guidance, since timing and starting dose depend on your current dose, tolerance and history. Read more in our guide to switching from semaglutide to tirzepatide.

Do both cause nausea?

Yes, nausea and other stomach-related effects are common with both, mostly during dose increases. Tell your clinician if symptoms are severe or persistent.

Are Zepbound and Mounjaro the same?

They contain the same active ingredient, tirzepatide, with different labeled indications. See Mounjaro vs. Zepbound.

How does Wegovy compare with Ozempic?

Both contain semaglutide but are approved for different uses and dosed differently. Our Wegovy vs. Ozempic page covers it.

Will insurance cover either one?

It depends on your plan and diagnosis. Check with your insurer, and our team can help you understand what documentation is typically needed.

Do I have to stay on it forever?

Both labels describe use alongside diet and activity to reduce weight and maintain the reduction long term. Duration is a decision made with your clinician; at CardioMender we plan for maintenance and lifestyle habits from the start.

Serving patients from South Florida at our Pembroke Pines, FL clinic. To talk with a clinician about which option may fit you, request a consultation or call (954) 799-6439.

←
Previous Article
Retatrutide vs. Tirzepatide: Is the Next-Gen Triple-Agonist Worth Switching For?
Take The Next Step

Start Your Transformation
with CardioMender, MD

Our physician-supervised weight loss and aesthetic programs are designed around your unique body, goals, and lifestyle.

Back To Top